BCL2A1 and ovarian carcinoma: Similarly, herein, a BCL2A1 promoter-luciferase assay, overexpression, depletion of RELA by RNAi, or inhibition by pharmaceutical approaches in ovarian cancer cells suggest that NF-ĸB signaling is the upstream regulator of BCL2A1 transcriptional activity.